Viewing
|Articles|December 22, 2010

Novartis completes Alcon acquisition.

Novartis has agreed to purchase the remaining 23% of their share in Alcon for $168 per share.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Subscribe

Latest CME